Gene Logic Shareholders Approve Genomics Assets Sale and Company Name Change to Ore Pharmaceuticals
11 12์ 2007 - 8:00PM
Business Wire
Gene Logic Inc. (NASDAQ:GLGC) announced today that the Company๏ฟฝs
shareholders have approved both the sale of its Genomics Assets to
Ocimum Biosolutions and the renaming of the Company as Ore
Pharmaceuticals Inc. The shareholder vote yesterday and completion
of the sale of the Genomics Assets expected later this week will
launch effectively Ore Pharmaceuticals as a new company focused on
drug repositioning and development. After the filing of necessary
legal documents later this week, the Company will be renamed Ore
Pharmaceuticals Inc. The Company๏ฟฝs stock will continue to trade on
the NASDAQ exchange and its stock ticker will change to ORXE.
Ownership of the name Gene Logic will transfer to Ocimum on the
date of closing of the sale agreement. ๏ฟฝEffective with the closing
of the Ocimum transaction, we will inaugurate a new company with a
clearly defined purpose,๏ฟฝ stated Charles L. Dimmler, III, President
and Chief Executive Officer of Gene Logic Inc. ๏ฟฝAs a drug
repositioning and development company, our sole purpose is to
supply the demand of pharmaceutical companies for product
innovation to enrich their development pipelines. Our shareholders๏ฟฝ
votes signify their endorsement of our strategy to transform the
company, a transformation we have been engaged in for the past
year. We are positioned well, with the industry๏ฟฝs leading
indication-seeking program, partnerships with eight pharmaceutical
companies, and a drug candidate of our own, GL1001, for which we
are seeking a development partner.๏ฟฝ Ore Pharmaceuticals will be
engaged exclusively in repositioning clinical-stage drug candidates
that have stalled in development for reasons other than safety. The
Company obtains these drug candidates from its pharmaceutical
partners and applies its proprietary integrative pharmacology
program to determine new potential therapeutic indications to
enable its partners to return such compounds to clinical
development. When the Company identifies and validates a new
potential indication for a compound and the partner reinstates that
compound into their clinical development program, the Company earns
success-based payments upon achievement of certain development
milestones. Additionally, in the event that a partner returns a
drug to the commercial market, the Company earns royalties on
sales. In most cases, the Company is entitled to obtain development
rights to repositioned drug candidates that its partners choose not
to reinstate into development. The Company has one such drug
candidate, GL1001, that demonstrated indications of efficacy at
relevant doses in in vivo testing for inflammatory bowel disease
(IBD). Based on the test results and market opportunities in IBD,
the Company is seeking a partner for the clinical development of
GL1001. Company Overview Headquartered in Gaithersburg, Maryland,
the Company๏ฟฝs indication discovery technologies are currently
applied at its facilities in Cambridge, Massachusetts on behalf of
a number of top pharmaceutical companies. These companies have
provided compounds which have failed advanced clinical studies for
reasons other than safety.
Gene Logic Inc. (MM) (NASDAQ:GLGC)
๊ณผ๊ฑฐ ๋ฐ์ดํฐ ์ฃผ์ ์ฐจํธ
๋ถํฐ 11์(11) 2024 ์ผ๋ก 12์(12) 2024
Gene Logic Inc. (MM) (NASDAQ:GLGC)
๊ณผ๊ฑฐ ๋ฐ์ดํฐ ์ฃผ์ ์ฐจํธ
๋ถํฐ 12์(12) 2023 ์ผ๋ก 12์(12) 2024
Gene Logic Inc. (MM) (๋์ค๋ฅ)์ ์ค์๊ฐ ๋ด์ค: ์ต๊ทผ ๊ธฐ์ฌ 0
More Gene Logic Inc. News Articles